-
Iran Guards say won't reopen Hormuz without US meeting all Tehran's conditions
-
South Korea FA apologises after sex scandal adds to controversies
-
Messi absent after father's death as Miami lose in Leagues Cup
-
Indonesia closes national park as wildfire spreads
-
Flight cancellations, evacuations in China as Typhoon Dolphin looms
-
ZXMoto leads China's charge to dominate the global motorbike market
-
Iran issues demands for reopening of Hormuz
-
Top-ranked Sabalenka, Pegula stunned in Toronto fourth round
-
Afghanistan's gold rush upends lives and landscapes
-
Japan nuclear debate unnerves proponents of pacifism
-
Messi missing after father's death as Miami lose in Leagues Cup
-
Spanish teen Jodar ousts eighth seed Lehecka at Montreal
-
World number one Sabalenka ousted in Toronto by Alexandrova
-
Angers mounts in US over vast network of car license plate cams
-
Olympic weightlifter hoists debris for Venezuela earthquake recovery
-
Darderi to face Nakashima in Montreal quarter-finals
-
FIFA condemns 'concerted and ongoing effort' to weaken Infantino
-
Espresso power fires Darderi past Borges in Montreal
-
South Africa win after surviving late Argentina surge
-
Shnaider upsets Pegula to book Toronto quarter-final with Swiatek
-
Man Utd boss Carrick being 'careful' with Mount as Man Utd draw with PSG
-
Mount injury overshadows Man Utd draw with Paris Saint-Germain
-
All Black Tuipulotu surprised after Sharks include Nonu
-
Ukraine denies targeting Bulgaria as drone explodes near pipeline
-
Infantino denies allegations of affair, favouritism while at UEFA: report
-
Vollering grabs Tour de France lead in Nice
-
MotoGP leader Martin soars to victory in British GP sprint race
-
Euros to showcase new TV guidelines on non-sexualisation of women athletes
-
Mosimane set to succeed Broos as South Africa coach
-
'Calm' Kiss savours first win as Wallabies boss
-
Drone enters Bulgaria, explodes near pipeline at Romanian border
-
Duplantis bids for fourth European title as stars align in Birmingham
-
Paris orders e-scooter users to wear helmets, reflective gear
-
Ukraine warns of tough winter as Russia strikes kill 4 in Kyiv region
-
Lionel Messi's father Jorge dies aged 68
-
Recovering Marchand to skip medleys at European swim champs
-
Johnson reveals 'stress' of Grand Slam Track collapse, clarifies payment
-
MotoGP leader Martin speeds to British Grand Prix pole
-
Defending champion Ferrand-Prevot out of Tour de France Femmes
-
Drone enters Bulgaria, explodes near pipeline at Romanian border: Bulgarian PM
-
Wallabies squeeze past Japan to give Kiss a winning start
-
Arsenal sign Brazil midfielder Guimaraes from Newcastle
-
Kyiv mourns recovery volunteer, whose life 'intertwined with the fallen'
-
Atletico will not sell Alvarez, says Simeone
-
Only two vehicles earn perfect child-seat scores for 2026
-
Ford Fathom turns affordable electric pickup into reality
-
Chinese car brands reshape Australia’s automotive market
-
Lise Klaveness, the Norwegian thorn in Infantino's side
-
Electric cars enter their most decisive generation yet
-
Europe’s electric car boom exposes a widening market divide
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
F.Ferraz--PC